Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

REGENERON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

06/16/2021 | 04:38pm EDT

Item 5.07. Submission of Matters to a Vote of Security Holders.





At the 2021 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc.
("Regeneron" or the "Company") held on June 11, 2021, Regeneron's shareholders
voted on the matters set forth below.



Proposal 1 - Election of Directors

The following nominees for Class III directors were elected to serve until the
2024 Annual Meeting of Shareholders and until their successors are duly elected
and qualified based upon the following votes:



Nominee                                     For            Against         Abstain        Broker Non-Votes
N. Anthony Coles, M.D.                    75,381,886       32,535,136      
  78,137              5,619,610
Arthur F. Ryan                            86,030,481       21,860,350        104,328              5,619,610
George L. Sing                            54,880,615       53,055,342         59,202              5,619,610
Marc Tessier-Lavigne, Ph.D.               72,073,887       35,848,999      
  72,273              5,619,610



Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021 was approved based upon the following votes:



For:       109,498,984
Against:     4,057,028
Abstain:        58,757

© Edgar Online, source Glimpses

All news about REGENERON PHARMACEUTICALS
09:42aREGENERON PHARMACEUTICALS : AstraZeneca to Co-Develop, Commercialize New Small M..
MT
07:01aREGENERON PHARMACEUTICALS : and AstraZeneca to Research, Develop and Commerciali..
PR
07/23REGENERON PHARMACEUTICALS : RBC Raises Price Target on Regeneron Pharmaceuticals..
MT
07/20Agilent Technologies PharmDx Assay Receives Expanded Use in EU
MT
07/20REGENERON PHARMACEUTICALS : Antibody Cocktail Gets Full Approval in Japan as Tre..
MT
07/20REGENERON PHARMACEUTICALS : Japan Becomes First Country to Approve Regeneron Ant..
PR
07/20Regeneron Pharmaceuticals, Inc. Announces Japan Becomes First Country to Appr..
CI
07/19Roche's Ronapreve Treatment for Covid-19 Approved by Japan
DJ
07/19Chugai Pharmaceutical Obtains Approval for Covid Antibody Cocktail
DJ
07/19EU evaluates Sobi arthritis drug to treat COVID-19 with pneumonia
RE
More news
Financials (USD)
Sales 2021 12 231 M - -
Net income 2021 4 984 M - -
Net cash 2021 9 191 M - -
P/E ratio 2021 12,4x
Yield 2021 -
Capitalization 60 167 M 60 167 M -
EV / Sales 2021 4,17x
EV / Sales 2022 4,39x
Nbr of Employees 9 447
Free-Float 82,2%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 581,01 $
Average target price 638,39 $
Spread / Average Target 9,88%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS19.60%59 833
GILEAD SCIENCES, INC.18.01%86 563
BIONTECH SE251.15%69 138
WUXI APPTEC CO., LTD.28.80%67 035
VERTEX PHARMACEUTICALS-15.83%51 496
GENMAB A/S13.72%29 074